Holen Sie sich die Stockscreener-App
2.325
2.30%
-0.065
Schlusskurs vom Vortag:
$2.39
Offen:
$2.31
24-Stunden-Volumen:
257.58K
Relative Volume:
0.32
Marktkapitalisierung:
$186.17M
Einnahmen:
$63.63M
Nettoeinkommen (Verlust:
$10.62M
KGV:
46.50
EPS:
0.05
Netto-Cashflow:
$-8.64M
1W Leistung:
+1.52%
1M Leistung:
-3.91%
6M Leistung:
-22.17%
1J Leistung:
+82.42%
1-Tages-Spanne:
$2.2501
$2.38
1-Wochen-Bereich:
$2.22
$2.42
52-Wochen-Spanne:
$1.16
$3.10
Protalix BioTherapeutics Inc. Stock (PLX) Company Profile
Firmenname
Protalix BioTherapeutics Inc.
Sektor
Branche
Telefon
972 4 988 9488
Adresse
2 Snunit Street, Science Park PO Box 455, Karmiel
Vergleichen Sie PLX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PLX
Protalix BioTherapeutics Inc.
|
2.335 | 190.56M | 63.63M | 10.62M | -8.64M | 0.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.22 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
629.22 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.73 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
837.59 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
183.82 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Protalix BioTherapeutics Inc. Stock (PLX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-06-08 | Bestätigt | H.C. Wainwright | Buy |
| 2017-04-17 | Bestätigt | Rodman & Renshaw | Buy |
| 2016-04-04 | Eingeleitet | Rodman & Renshaw | Buy |
| 2015-04-23 | Hochstufung | Jefferies | Hold → Buy |
| 2014-11-12 | Bestätigt | R. F. Lafferty | Buy |
| 2014-01-24 | Eingeleitet | R. F. Lafferty | Buy |
| 2012-05-02 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2012-05-02 | Bestätigt | Oppenheimer | Outperform |
| 2012-04-30 | Herabstufung | Auriga | Buy → Hold |
| 2011-10-13 | Eingeleitet | Morgan Joseph | Hold |
| 2011-03-17 | Herabstufung | WBB Securities | Strong Buy → Buy |
| 2010-11-09 | Bestätigt | Oppenheimer | Outperform |
| 2010-10-14 | Bestätigt | UBS | Buy |
| 2009-12-02 | Bestätigt | Hapoalim | Outperform |
| 2009-09-22 | Eingeleitet | Canaccord Adams | Buy |
| 2009-09-02 | Eingeleitet | Hapoalim | Outperform |
| 2008-12-01 | Bestätigt | Oppenheimer | Outperform |
| 2008-03-11 | Eingeleitet | UBS | Buy |
| 2007-11-20 | Eingeleitet | CIBC Wrld Mkts | Sector Outperform |
Alle ansehen
Protalix BioTherapeutics Inc. Aktie (PLX) Neueste Nachrichten
How Protalix BioTherapeutics Inc. (DE) stock performs in volatility spikesJuly 2025 Review & Daily Technical Forecast Reports - newser.com
Protalix and Chiesi seek EMA re-examination of Elfabrio dosing opinion - Proactive financial news
Chiesi and Protalix seek review of EMA’s negative opinion on Elfabrio - Investing.com Australia
Real time scanner hits for Protalix BioTherapeutics Inc. explainedMarket Risk Report & Community Trade Idea Sharing Platform - newser.com
How to integrate Protalix BioTherapeutics Inc. into portfolio analysis toolsEarnings Recap Report & Weekly Top Gainers Alerts - newser.com
Relative strength of Protalix BioTherapeutics Inc. in sector analysisPortfolio Update Summary & Daily Stock Momentum Reports - newser.com
What makes Protalix BioTherapeutics Inc. stock attractive to growth fundsJuly 2025 Short Interest & Fast Entry and Exit Trade Plans - newser.com
Is Protalix BioTherapeutics Inc. (PBDA) stock a contrarian opportunityJuly 2025 Recap & Fast Gain Swing Alerts - newser.com
Analyzing recovery setups for Protalix BioTherapeutics Inc. investorsCPI Data & Expert Approved Momentum Ideas - newser.com
Custom strategy builders for tracking Protalix BioTherapeutics Inc.July 2025 Gainers & Low Drawdown Momentum Trade Ideas - newser.com
How Protalix BioTherapeutics Inc. stock reacts to job market dataCPI Data & Fast Gaining Stock Strategy Reports - newser.com
Is Protalix BioTherapeutics Inc. still worth holding after the dipMarket Movement Recap & Stepwise Trade Signal Implementation - newser.com
How Protalix BioTherapeutics Inc. (PBDA) stock behaves under inflation pressureStock Surge & Real-Time Market Sentiment Alerts - newser.com
Is Protalix BioTherapeutics Inc. stock attractive for passive investors2025 Market Overview & Trade Opportunity Analysis - newser.com
What Wall Street predicts for Protalix BioTherapeutics Inc. stock priceTrade Signal Summary & High Win Rate Trade Tips - newser.com
Chiesi and Protalix seek review of EMA’s negative opinion on Elfabrio By Investing.com - Investing.com South Africa
Protalix Seeks EMA Re-examination for Elfabrio Dosing - TipRanks
Chiesi Global Rare Diseases and Protalix BioTherapeutics Seek Re-examination from the EMA for the Negative Opinion for Elfabrio (pegunigalsidase alfa) Alternative Dosing Regimen of Every Four Weeks in the EU - The Manila Times
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Protalix BioTherapeutics, Inc. (PLX) And Encourages Shareholders to Reach Out - ACCESS Newswire
Why Protalix BioTherapeutics Inc. (DE) stock attracts wealthy investorsBuy Signal & Fast Gain Swing Alerts - newser.com
Is Protalix BioTherapeutics Inc. stock positioned for long term growth2025 Market Sentiment & Free Safe Capital Growth Stock Tips - newser.com
Can Protalix BioTherapeutics Inc. stock deliver consistent earnings growth - newser.com
News impact scoring models applied to Protalix BioTherapeutics Inc.July 2025 Snapshot & Fast Moving Stock Watchlists - newser.com
How Protalix BioTherapeutics Inc. (PBDA) stock trades in high volatilityWeekly Trade Review & Free High Accuracy Swing Entry Alerts - newser.com
Automated trading signals detected on Protalix BioTherapeutics Inc.Weekly Investment Summary & Real-Time Market Sentiment Reports - newser.com
Will Protalix BioTherapeutics Inc. stock benefit from AI adoption2025 Dividend Review & Entry Point Confirmation Signals - newser.com
How Protalix BioTherapeutics Inc. stock performs in weak economyEntry Point & High Accuracy Trade Signal Alerts - newser.com
Will breakout in Protalix BioTherapeutics Inc. lead to full recovery2025 Trade Ideas & AI Powered Market Entry Strategies - newser.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Protalix BioTherapeutics, Inc. (PLX) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Will Protalix BioTherapeutics Inc. stock benefit from automation2025 Performance Recap & Step-by-Step Swing Trade Plans - newser.com
PLX Investors Have Opportunity to Join Protalix BioTherapeutics, Inc. Fraud Investigation with the Schall Law Firm - The AI Journal
Protalix BioTherapeutics, Inc. (PLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Finanzdaten der Protalix BioTherapeutics Inc.-Aktie (PLX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.19%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):